LOZOL
LOE ApproachingNDAORALTABLET
Approved
Jul 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOZOL is an oral tablet small-molecule drug approved in 1983 by Sanofi under NDA. The mechanism of action and specific indications are not publicly detailed in available data, limiting clarity on therapeutic positioning.
LOE Approaching
Product faces imminent loss of exclusivity with moderate competitive pressure (30/100), signaling potential team downsizing or transition planning within the next 1–3 years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings signal declining investment and team contraction on this legacy product. Career progression on LOZOL is limited; professionals should anticipate role consolidation, redeployment, or exit as LOE approaches.
Brand ManagerSales Representative
Worked on LOZOL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.